IN165717B
(fr)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
FI102355B
(fi)
*
|
1988-02-11 |
1998-11-30 |
Squibb Bristol Myers Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
ATE120374T1
(de)
*
|
1989-07-20 |
1995-04-15 |
Sandoz Ag |
Markierte polypeptidderivate.
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
CA2070416A1
(fr)
*
|
1989-10-23 |
1991-04-24 |
Richard Ingram |
Inhibiteurs polypeptidiques du gamma-interferon
|
CA2076678C
(fr)
*
|
1990-03-02 |
1999-09-28 |
Diane Williams |
Toxines chimeres ameliorees
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
DK0485563T3
(da)
*
|
1990-05-30 |
1995-03-20 |
Deutsches Krebsforsch |
Polyethersubstituerede antitumormidler
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
AU657910B2
(en)
*
|
1990-07-05 |
1995-03-30 |
Akzo N.V. |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
WO1992005802A1
(fr)
*
|
1990-09-28 |
1992-04-16 |
Neorx Corporation |
Porteurs polymeres servant a la liberation d'agents a liaison covalente
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
JP3693671B2
(ja)
*
|
1991-03-15 |
2005-09-07 |
アムゲン インコーポレーテッド |
ポリペプチドのpeg化
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
DE69112053D1
(de)
*
|
1991-07-22 |
1995-09-14 |
Bracco Int Bv |
Anwendung von Chelaten von Konjugaten mit paramagnetischen Metallen für Targetting.
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
EP0563475B1
(fr)
*
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Conjugués d'agents ciblés et de dérivés du CC-1065
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
DE69328092T2
(de)
*
|
1992-05-28 |
2000-07-20 |
Univ Toledo |
Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
|
US5916772A
(en)
*
|
1992-06-16 |
1999-06-29 |
Whittier Institute For Diabetes And Endocrinology |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
ES2149823T3
(es)
*
|
1992-09-03 |
2000-11-16 |
Univ California |
Factor y composiciones que afectan al tejido dorsal.
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
US6001364A
(en)
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
DK0697891T3
(da)
|
1993-05-05 |
2000-09-04 |
Keith Rose |
Polyoximforbindelser og fremstilling deraf
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6214345B1
(en)
*
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
PT648503E
(pt)
*
|
1993-09-22 |
2000-11-30 |
Hoechst Ag |
Pro-profarmacos, sua producao e utilizacao
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
CA2137639C
(fr)
*
|
1993-12-09 |
1999-01-26 |
Agustin B. L. Davila |
Composition vaccinale comprenant un facteur de croissance epidermique autologue ou encore un fragmant ou un derive de celui-ci qui manifeste une activite antitumorale, et son emploi dans la lutte contre les affections malignes
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
DE69529572T2
(de)
*
|
1994-11-10 |
2003-06-18 |
Univ Kentucky Res Foundation L |
Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
ATE234635T1
(de)
*
|
1995-12-22 |
2003-04-15 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
WO1997033552A1
(fr)
|
1996-03-12 |
1997-09-18 |
Pg-Txl Company, L.P. |
Bioprecurseurs de paclitaxel solubles dans l'eau
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
WO1998047496A2
(fr)
*
|
1997-04-18 |
1998-10-29 |
Access Pharmaceuticals, Inc. |
Composes a base de polymere et de platine
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
AU746423B2
(en)
*
|
1997-05-05 |
2002-05-02 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
AU764603B2
(en)
*
|
1998-07-17 |
2003-08-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Water-soluble drugs and methods for their production
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
US20010036635A1
(en)
|
2000-03-27 |
2001-11-01 |
Waldman Scott A. |
Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
|
DK1286704T3
(da)
|
2000-06-02 |
2014-09-22 |
Univ Texas |
Ethylendicystein (EC)-glucose analoge konjugater
|
WO2002002147A2
(fr)
*
|
2000-06-30 |
2002-01-10 |
Board Of Regents, The University Of Texas System |
Isolement d'un peptide d'internalisation specifique des cellules infiltrant les tissus tumoraux pour liberation medicamenteuse ciblee
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
CZ20031262A3
(en)
*
|
2000-10-16 |
2004-03-17 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
US6906182B2
(en)
|
2000-12-01 |
2005-06-14 |
Cell Works Therapeutics, Inc. |
Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
CA2444383A1
(fr)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT2163256E
(pt)
|
2001-05-11 |
2015-11-20 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
WO2002094271A1
(fr)
*
|
2001-05-15 |
2002-11-28 |
Faulk Pharmaceuticals, Inc. |
Administration ciblee de composes bioactifs pour le traitement du cancer
|
CA2447335C
(fr)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Administration ciblee de medicaments pour le traitement d'infections virales
|
CA2451511A1
(fr)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Eleuthesides antimitotiques
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
WO2003072735A2
(fr)
*
|
2002-02-22 |
2003-09-04 |
New River Pharmaceuticals Inc. |
Utilisation de la conjugaison peptide-medicament pour diminuer la variabilite entre sujets de niveaux de serum de medicament
|
JP4878732B2
(ja)
*
|
2002-02-22 |
2012-02-15 |
シャイア エルエルシー |
規制物質の濫用を防ぐための新規な持続放出製薬化合物
|
EP1490090A4
(fr)
|
2002-02-22 |
2006-09-20 |
New River Pharmaceuticals Inc |
Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
CA2499550C
(fr)
|
2002-09-20 |
2013-10-15 |
Alpharma, Inc. |
Sous-unite de sequestration et compositions et procedes associes
|
JP2006515835A
(ja)
*
|
2002-11-07 |
2006-06-08 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
組織特異的疾患のイメージングのための、エチレンジシステイン(ec)−薬物結合体、組成物、および方法
|
JP4740862B2
(ja)
|
2003-05-07 |
2011-08-03 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
合金化された半導体量子ドットおよび合金化された濃度勾配量子ドット、これらの量子ドットを含むシリーズ、ならびにこれらに関する方法
|
SI1644019T2
(en)
*
|
2003-05-29 |
2018-04-30 |
Shire Llc |
AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE
|
WO2005016368A2
(fr)
*
|
2003-08-19 |
2005-02-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methode permettant d'induire la biomineralisation, methode permettant d'induire la regeneration osseuse et methodes associees
|
BRPI0414876A
(pt)
*
|
2003-09-30 |
2006-11-21 |
New River Pharmaceuticals Inc |
compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
|
WO2005040170A2
(fr)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
|
WO2005055931A2
(fr)
|
2003-12-03 |
2005-06-23 |
University Of Medicine And Dentistry Of New Jersey |
Procede pour empecher la survie des cellules retrovirales et la formation des retrovirus infectieux
|
DK1695991T3
(da)
*
|
2003-12-10 |
2010-04-19 |
Toudai Tlo Ltd |
Koordinationskompleks af diaminocuclohexan platin (II) med blokcopolymer indeholdende poly(carboxylsyre) segment og antitumormiddel omfattende samme
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
MXPA06011463A
(es)
|
2004-04-07 |
2007-04-25 |
Rinat Neuroscience Corp |
Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
EP1897900B1
(fr)
*
|
2005-06-09 |
2013-08-07 |
NanoCarrier Co., Ltd. |
Procede de fabrication d'un compose polymere coordonne d'un complexe de platine
|
US7867977B2
(en)
*
|
2005-11-03 |
2011-01-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
DK1969031T3
(da)
|
2005-12-05 |
2009-09-14 |
Nitto Denko Corp |
Polyglutamat-aminosyre-konjugater og fremgangsmåder
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
PT2484346T
(pt)
|
2006-06-19 |
2017-04-26 |
Alpharma Pharmaceuticals Llc |
Composições farmacêuticas
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
EP2431388A1
(fr)
|
2006-10-31 |
2012-03-21 |
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services |
Polypeptides lissés et procédés d'utilisation
|
AU2008206442B2
(en)
|
2007-01-12 |
2012-10-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
gp100-specific T cell receptors and related materials and methods of use
|
CN110613845A
(zh)
*
|
2007-01-25 |
2019-12-27 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
CA2680854C
(fr)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
|
JP2010526159A
(ja)
*
|
2007-04-10 |
2010-07-29 |
日東電工株式会社 |
多機能性ポリグルタミン酸塩薬物担体
|
JP2010528122A
(ja)
*
|
2007-05-09 |
2010-08-19 |
日東電工株式会社 |
白金薬剤と結合されたポリマー
|
JP5341879B2
(ja)
|
2007-05-09 |
2013-11-13 |
日東電工株式会社 |
疎水性化合物及びポリアミノ酸複合体を含む組成物
|
WO2008141110A2
(fr)
*
|
2007-05-09 |
2008-11-20 |
Nitto Denko Corporation |
Conjugués de polyglutamate et conjugués de polyglutamate-amino acide contenant une pluralité de médicaments
|
US9283276B2
(en)
|
2007-08-14 |
2016-03-15 |
Ludwig Institute For Cancer Research Ltd. |
Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
|
AU2008292910A1
(en)
*
|
2007-08-31 |
2009-03-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting Wip1, prodrugs and compositions thereof, and related methods
|
KR20100122510A
(ko)
*
|
2008-03-06 |
2010-11-22 |
닛토덴코 가부시키가이샤 |
중합체 파클리탁셀 접합체 및 암 치료 방법
|
WO2010075417A1
(fr)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteur de lymphocytes t spécifique de la survivine dans le traitement du cancer
|
WO2010075303A1
(fr)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Facteurs d'épissage avec un domaine de liaison à l'arn de protéine puf et domaine effecteur d'épissage et leurs utilisations
|
WO2010088160A1
(fr)
|
2009-01-28 |
2010-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs des lymphocytes t, matières correspondantes et procédés d'utilisation
|
WO2010106544A1
(fr)
*
|
2009-03-16 |
2010-09-23 |
Rajah Vijay Kumar |
Procédé et appareil de nanoperméabilisation par résonance focalisée(forn)
|
EP2411038B1
(fr)
|
2009-03-27 |
2016-12-28 |
Van Andel Research Institute |
Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
US8603814B2
(en)
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
WO2011032099A1
(fr)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Méthodes pour traiter un disfonctionnement diastolique et états associés
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US8465743B2
(en)
|
2009-10-01 |
2013-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
EP2488637B1
(fr)
|
2009-10-16 |
2015-12-23 |
The University Of British Columbia |
Compositions d'inhibiteurs de phosphatase et d'homologue de tensine (pten), utilisations et procédés
|
US20120208762A1
(en)
|
2009-10-27 |
2012-08-16 |
The Board Of Trustees Of The University Of Illinois |
Methods of Diagnosing Diastolic Dysfunction
|
CA2780572A1
(fr)
|
2009-11-13 |
2011-05-19 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Ligand de mort programmee 1 module
|
WO2011075393A2
(fr)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Co-agonistes du récepteur du glucagon/glp-i
|
WO2011094337A1
(fr)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
|
DK2547359T3
(en)
|
2010-03-15 |
2016-06-06 |
The Board Of Trustees Of The Univ Of Illionis |
Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
|
CA2811788C
(fr)
|
2010-09-21 |
2020-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recepteurs des cellules t anti-ssx-2, materiaux et procedes d'utilisation
|
WO2012054825A1
(fr)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs de lymphocytes t anti-mage-a3, matériaux associés et méthodes d'utilisation associées
|
WO2012087943A2
(fr)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
IL285335B2
(en)
|
2011-04-08 |
2023-12-01 |
Us Health |
Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
JP6100764B2
(ja)
|
2011-06-09 |
2017-03-22 |
アメリカ合衆国 |
免疫原性の低いt細胞及び/又はb細胞エピトープを有するシュードモナス外毒素a
|
PE20140724A1
(es)
|
2011-06-22 |
2014-07-10 |
Univ Indiana Res & Tech Corp |
Coagonistas del receptor de glucagon/glp-1
|
JP6415322B2
(ja)
|
2011-09-15 |
2018-10-31 |
アメリカ合衆国 |
Hla−a1−又はhla−cw7−拘束性mageを認識するt細胞受容体
|
US9206240B2
(en)
|
2011-09-16 |
2015-12-08 |
The United States of America, as represented by the Secretary, Department of Helath and Human Services |
Pseudomonas exotoxin A with less immunogenic B cell epitopes
|
WO2013059593A1
(fr)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs d'antigènes chimériques anti-cd22
|
KR20140097151A
(ko)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
NZ700362A
(en)
|
2012-04-11 |
2016-09-30 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
WO2013177247A1
(fr)
|
2012-05-22 |
2013-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs murins des lymphocytes t anti-ny-eso-1
|
SG11201408347UA
(en)
|
2012-06-14 |
2015-01-29 |
Ambrx Inc |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
WO2013192129A1
(fr)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Analogues du glucagon présentant une activité sur le récepteur du gip
|
SI2864350T1
(en)
|
2012-06-21 |
2018-08-31 |
Indiana University Research And Technology Corporation |
GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
|
KR102165350B1
(ko)
|
2012-09-14 |
2020-10-14 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
|
ES2718903T3
(es)
|
2012-10-24 |
2019-07-05 |
Us Health |
Receptores de antígenos quiméricos M971
|
WO2014160627A1
(fr)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Polypeptides anti-cd276, protéines, et récepteurs d'antigènes chimériques
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
JP6628719B2
(ja)
|
2013-07-15 |
2020-01-15 |
アメリカ合衆国 |
抗ヒトパピローマウイルス16 e6 t細胞受容体
|
CA2926215A1
(fr)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Exotoxine a de pseudomonas modifiee
|
WO2015084513A1
(fr)
|
2013-12-06 |
2015-06-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs antigéniques chimériques spécifiques du récepteur de lymphopoiétine stromale thymique et leurs procédés d'utilisation
|
IL292038A
(en)
|
2014-04-23 |
2022-06-01 |
Juno Therapeutics Inc |
Methods for enriching and producing immune cell populations for stress treatment
|
WO2015184228A1
(fr)
|
2014-05-29 |
2015-12-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs de lymphocytes t anti-papillomavirus humain 16 e7
|
MX2016015834A
(es)
|
2014-06-02 |
2017-07-19 |
Us Health |
Receptores quiméricos de antigeno que tienen como diana a cd-19.
|
EP3169773B1
(fr)
|
2014-07-15 |
2023-07-12 |
Juno Therapeutics, Inc. |
Cellules modifiées pour thérapie cellulaire adoptive
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
WO2016064929A1
(fr)
|
2014-10-20 |
2016-04-28 |
Juno Therapeutics, Inc. |
Procédés et compositions pour dosage en thérapie cellulaire adoptive
|
WO2016071343A1
(fr)
|
2014-11-03 |
2016-05-12 |
Immures S.R.L. |
Récepteurs de lymphocytes t
|
CA2966538A1
(fr)
|
2014-11-05 |
2016-05-12 |
Juno Therapeutics, Inc. |
Procedes de transduction et de traitement de cellules
|
CA2969456A1
(fr)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Procedes et compositions pour therapie cellulaire adoptive
|
ES2818103T3
(es)
|
2015-01-16 |
2021-04-09 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
|
WO2016166568A1
(fr)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil permettant d'augmenter une population de cellules
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017068419A2
(fr)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Procédés, kits, agents et appareils de transduction
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079703A1
(fr)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive
|
MA43380A
(fr)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
Récepteurs chimériques modifiés et compositions et procédés associés
|
WO2017096331A1
(fr)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
EP3430548A1
(fr)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
US11518814B2
(en)
|
2016-03-22 |
2022-12-06 |
Seattle Children's Hospital |
Early intervention methods to prevent or ameliorate toxicity
|
WO2017193107A2
(fr)
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Cellules génétiquement modifiées et leurs procédés de fabrication
|
JP2019517518A
(ja)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
早期治療選択肢としての養子細胞療法
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
WO2018005559A1
(fr)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
WO2018005759A1
(fr)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibiteur de la dégradation de l'hème pour améliorer le traitement antibiotique de l'infection par mycobacterium tuberculosis.
|
EP3490585B1
(fr)
|
2016-07-29 |
2023-05-17 |
Juno Therapeutics, Inc. |
Polypeptides immunomdulateurs et compositions et procédés associés
|
JP2019536437A
(ja)
|
2016-10-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Hpv特異的結合分子
|
WO2018102612A1
(fr)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Cellules b modifiées et compositions et méthodes associées
|
BR112019011065A2
(pt)
|
2016-12-03 |
2019-10-01 |
Juno Therapeutics Inc |
métodos para determinação da dosagem de células t car
|
KR20190104529A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포의 조절 방법
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
US11821027B2
(en)
|
2017-01-10 |
2023-11-21 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
MX2019008538A
(es)
|
2017-01-20 |
2019-11-05 |
Juno Therapeutics Gmbh |
Conjugados de superficie celular y composiciones y métodos celulares relacionados.
|
CN110582288A
(zh)
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
AU2018250336A1
(en)
|
2017-04-07 |
2019-09-26 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
CA3060526A1
(fr)
|
2017-04-27 |
2018-11-01 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomeres et leurs methodes d'utilisation
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
EP3631468A1
(fr)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
CN111954679A
(zh)
|
2017-10-03 |
2020-11-17 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
EP3704230A1
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
CA3080509A1
(fr)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Procede pour la production d'une composition de lymphocytes t
|
BR112020008478A2
(pt)
|
2017-11-01 |
2020-10-20 |
Editas Medicine, Inc. |
métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞成熟抗原(bcma)に特異的なキメラ抗原受容体
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
WO2019090202A1
(fr)
|
2017-11-06 |
2019-05-09 |
Editas Medicine, Inc. |
Procédés, compositions et composants pour l'édition crispr-cas9 de cblb dans des lymphocytes t pour l'immunothérapie
|
WO2019109053A1
(fr)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
WO2019113557A1
(fr)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Procédé de production d'une compositions de lymphocytes t modifiés
|
EP3720480A2
(fr)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Marqueurs phénotypiques pour thérapie cellulaire et procédés associés
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
US11779602B2
(en)
|
2018-01-22 |
2023-10-10 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
PE20201345A1
(es)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
Receptores de celulas t, y celulas disenadas que expresan los mismos
|
JP2021520202A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
JP2021520211A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するt細胞、関連ポリヌクレオチド、および方法
|
AU2019318560A1
(en)
|
2018-08-09 |
2021-02-25 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
EP3833759A1
(fr)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Procédés pour évaluer des acides nucléiques intégrés
|
WO2020043899A1
(fr)
|
2018-08-31 |
2020-03-05 |
Invectys |
Récepteurs d'antigènes chimériques contre de multiples isoformes de hla-g
|
KR20210098450A
(ko)
|
2018-10-31 |
2021-08-10 |
주노 테라퓨틱스 게엠베하 |
세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
|
US20210393689A1
(en)
|
2018-11-01 |
2021-12-23 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
BR112021008289A2
(pt)
|
2018-11-01 |
2021-10-26 |
Juno Therapeutics, Inc. |
Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
WO2020113188A2
(fr)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Méthodes de dosage et de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
SG11202105502RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for treatment using adoptive cell therapy
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
CA3136618A1
(fr)
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Recepteurs antigeniques chimeriques specifiques de flt3 et leurs procedes d'utilisation
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
IL288284B1
(en)
|
2019-05-22 |
2024-02-01 |
Massachusetts Inst Technology |
Circular Rana preparations and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
MX2022006715A
(es)
|
2019-12-06 |
2022-09-23 |
Juno Therapeutics Inc |
Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
|
EP4097218A1
(fr)
|
2020-01-28 |
2022-12-07 |
Juno Therapeutics, Inc. |
Procédés pour la transduction de lymphocytes t
|
US20230149462A1
(en)
|
2020-04-10 |
2023-05-18 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
US20240042015A1
(en)
|
2020-05-19 |
2024-02-08 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2021260186A1
(fr)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Lymphocytes t modifiés exprimant un récepteur recombiné, polynucléotides et procédés associés
|
EP4240756A1
(fr)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
WO2022234009A2
(fr)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Méthodes de stimulation et de transduction de lymphocytes t
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(fr)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Récepteurs antigéniques chimériques spécifiques de l'antigène de maturation des cellules b destinés à être utilisés dans le traitement d'un myélome
|
CA3236235A1
(fr)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Compositions de nanoparticules lipidiques pour l'administration de polynucleotides circulaires
|
WO2023081900A1
(fr)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
|
WO2023164440A1
(fr)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Lymphocytes t de récepteur d'auto-anticorps chimérique de protéinase 3 (pr3) et méthodes et utilisations associées
|
WO2023220655A1
(fr)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
|
WO2023230548A1
(fr)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
|
WO2023231959A2
(fr)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Compositions d'arn circulaire synthétiques et leurs procédés d'utilisation
|
WO2023250400A1
(fr)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
|
WO2024006960A1
(fr)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Nanoparticules lipidiques pour l'administration d'acides nucléiques
|
WO2024031091A2
(fr)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Récepteurs antigéniques chimériques spécifiques de gprc5d et bcma
|
WO2024102762A1
(fr)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipides et compositions de nanoparticules lipidiques pour administration de polynucléotides
|
WO2024102730A1
(fr)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipides et compositions de nanoparticules pour l'administration de polynucléotides
|